Vaccinex, Inc. - Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC

Monday, April 1, 2019 1:00 p.m. ET  

Supporting Materials

Title
Vaccinex, Inc. - Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC
Date / Time
04/01/19 1:00 p.m. ET